Concepts (185)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hemophilia A | 10 | 2022 | 49 | 1.520 |
Why?
|
| Hemorrhage | 8 | 2021 | 75 | 0.620 |
Why?
|
| Hemophilia B | 4 | 2020 | 10 | 0.470 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 2 | 2023 | 9 | 0.450 |
Why?
|
| Factor VIII | 7 | 2023 | 32 | 0.400 |
Why?
|
| Venous Thromboembolism | 3 | 2020 | 35 | 0.350 |
Why?
|
| Heparin | 2 | 2020 | 22 | 0.340 |
Why?
|
| Hemarthrosis | 3 | 2021 | 22 | 0.330 |
Why?
|
| Anticoagulants | 2 | 2020 | 85 | 0.320 |
Why?
|
| Pipecolic Acids | 1 | 2008 | 1 | 0.300 |
Why?
|
| Factor IX | 2 | 2020 | 6 | 0.290 |
Why?
|
| Thrombocytopenia | 1 | 2008 | 21 | 0.290 |
Why?
|
| Autoantibodies | 3 | 2006 | 64 | 0.290 |
Why?
|
| Recombinant Proteins | 3 | 2017 | 180 | 0.270 |
Why?
|
| von Willebrand Factor | 4 | 2023 | 11 | 0.240 |
Why?
|
| Exercise Therapy | 1 | 2006 | 91 | 0.240 |
Why?
|
| Humans | 26 | 2023 | 25973 | 0.230 |
Why?
|
| Thrombophilia | 2 | 2020 | 6 | 0.230 |
Why?
|
| Hemostasis | 2 | 2016 | 11 | 0.220 |
Why?
|
| Blood Coagulation Disorders | 1 | 2004 | 13 | 0.210 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2004 | 15 | 0.210 |
Why?
|
| Hemostatics | 1 | 2023 | 11 | 0.210 |
Why?
|
| Adult | 13 | 2023 | 7666 | 0.210 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2020 | 29 | 0.200 |
Why?
|
| Sex Chromosome Disorders | 1 | 2022 | 1 | 0.200 |
Why?
|
| Leukemia, Promyelocytic, Acute | 1 | 2002 | 5 | 0.190 |
Why?
|
| Hematologic Diseases | 1 | 2002 | 10 | 0.190 |
Why?
|
| Adolescent | 7 | 2023 | 2100 | 0.180 |
Why?
|
| Young Adult | 7 | 2023 | 1942 | 0.180 |
Why?
|
| Physical Therapists | 1 | 2021 | 5 | 0.170 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2020 | 36 | 0.170 |
Why?
|
| Treatment Adherence and Compliance | 1 | 2020 | 3 | 0.170 |
Why?
|
| Serum Albumin | 1 | 2020 | 23 | 0.170 |
Why?
|
| Genetic Variation | 2 | 2017 | 94 | 0.160 |
Why?
|
| Autoimmune Diseases | 3 | 2006 | 26 | 0.160 |
Why?
|
| Health Literacy | 1 | 2021 | 106 | 0.150 |
Why?
|
| Anemia, Sickle Cell | 1 | 2018 | 12 | 0.150 |
Why?
|
| Erythrocyte Transfusion | 1 | 2018 | 12 | 0.150 |
Why?
|
| Factor VIIa | 1 | 2017 | 8 | 0.140 |
Why?
|
| von Willebrand Disease, Type 2 | 1 | 2017 | 1 | 0.140 |
Why?
|
| Blood Coagulation | 1 | 2017 | 21 | 0.140 |
Why?
|
| Joint Diseases | 1 | 2018 | 115 | 0.130 |
Why?
|
| von Willebrand Disease, Type 1 | 1 | 2016 | 1 | 0.130 |
Why?
|
| Albumins | 1 | 2016 | 18 | 0.120 |
Why?
|
| Male | 11 | 2023 | 14280 | 0.120 |
Why?
|
| Child | 4 | 2023 | 1217 | 0.120 |
Why?
|
| Blood Coagulation Factors | 2 | 2006 | 19 | 0.110 |
Why?
|
| Arthroplasty, Replacement, Knee | 2 | 2012 | 609 | 0.110 |
Why?
|
| Middle Aged | 8 | 2020 | 8775 | 0.110 |
Why?
|
| Arthroplasty, Replacement, Hip | 2 | 2012 | 785 | 0.110 |
Why?
|
| United States | 4 | 2018 | 1990 | 0.090 |
Why?
|
| Megakaryocyte Progenitor Cells | 1 | 2011 | 1 | 0.090 |
Why?
|
| Dipeptidyl Peptidase 4 | 1 | 2011 | 4 | 0.090 |
Why?
|
| Female | 7 | 2023 | 14735 | 0.090 |
Why?
|
| Blood Loss, Surgical | 2 | 2011 | 55 | 0.080 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2020 | 105 | 0.080 |
Why?
|
| Arginine | 1 | 2008 | 17 | 0.070 |
Why?
|
| Thromboembolism | 1 | 2008 | 18 | 0.070 |
Why?
|
| Sulfonamides | 1 | 2008 | 44 | 0.070 |
Why?
|
| Clinical Trials as Topic | 1 | 2008 | 210 | 0.070 |
Why?
|
| Liver | 1 | 2008 | 143 | 0.070 |
Why?
|
| Risk Factors | 3 | 2020 | 2237 | 0.070 |
Why?
|
| Interferon-alpha | 1 | 2007 | 30 | 0.070 |
Why?
|
| Polyethylene Glycols | 1 | 2007 | 42 | 0.070 |
Why?
|
| Hepatitis C, Chronic | 1 | 2007 | 42 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2017 | 329 | 0.060 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2006 | 4 | 0.060 |
Why?
|
| Ankle Joint | 1 | 2006 | 43 | 0.060 |
Why?
|
| Anemia, Hemolytic | 1 | 2005 | 4 | 0.060 |
Why?
|
| Microcirculation | 1 | 2005 | 28 | 0.060 |
Why?
|
| Syndrome | 1 | 2005 | 73 | 0.060 |
Why?
|
| Phenotype | 2 | 2017 | 291 | 0.060 |
Why?
|
| Fever | 1 | 2005 | 34 | 0.060 |
Why?
|
| Treatment Outcome | 3 | 2016 | 3400 | 0.060 |
Why?
|
| Pneumonectomy | 1 | 2006 | 76 | 0.060 |
Why?
|
| Kidney Diseases | 1 | 2005 | 70 | 0.060 |
Why?
|
| von Willebrand Diseases | 1 | 2005 | 1 | 0.060 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2004 | 3 | 0.060 |
Why?
|
| Trophoblasts | 1 | 2004 | 2 | 0.060 |
Why?
|
| Deamino Arginine Vasopressin | 1 | 2005 | 5 | 0.060 |
Why?
|
| Adenocarcinoma | 1 | 2006 | 135 | 0.060 |
Why?
|
| Quality of Life | 2 | 2020 | 605 | 0.060 |
Why?
|
| Elbow Joint | 1 | 2006 | 126 | 0.060 |
Why?
|
| Diagnosis, Differential | 1 | 2005 | 337 | 0.060 |
Why?
|
| Inflammation Mediators | 1 | 2004 | 66 | 0.060 |
Why?
|
| Nervous System Diseases | 1 | 2005 | 115 | 0.050 |
Why?
|
| Hemorrhagic Disorders | 1 | 2004 | 1 | 0.050 |
Why?
|
| Paraproteins | 1 | 2004 | 1 | 0.050 |
Why?
|
| Fibrin | 1 | 2004 | 4 | 0.050 |
Why?
|
| Biopolymers | 1 | 2004 | 5 | 0.050 |
Why?
|
| Autoantigens | 1 | 2004 | 16 | 0.050 |
Why?
|
| ADAMTS13 Protein | 1 | 2023 | 5 | 0.050 |
Why?
|
| Pregnancy | 2 | 2020 | 327 | 0.050 |
Why?
|
| Plasma | 1 | 2023 | 15 | 0.050 |
Why?
|
| Apoptosis | 1 | 2004 | 209 | 0.050 |
Why?
|
| Surveys and Questionnaires | 2 | 2021 | 1107 | 0.050 |
Why?
|
| Comorbidity | 2 | 2018 | 476 | 0.050 |
Why?
|
| ADAM Proteins | 1 | 2023 | 41 | 0.050 |
Why?
|
| Range of Motion, Articular | 1 | 2006 | 709 | 0.050 |
Why?
|
| Lipoproteins | 1 | 2022 | 10 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2023 | 1758 | 0.050 |
Why?
|
| Immune Tolerance | 1 | 2001 | 12 | 0.050 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2022 | 86 | 0.050 |
Why?
|
| Elective Surgical Procedures | 2 | 2012 | 35 | 0.050 |
Why?
|
| Aged, 80 and over | 2 | 2017 | 4642 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2017 | 1702 | 0.050 |
Why?
|
| Child, Preschool | 1 | 2023 | 597 | 0.050 |
Why?
|
| Aged | 3 | 2020 | 8732 | 0.040 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2020 | 4 | 0.040 |
Why?
|
| North America | 1 | 2020 | 38 | 0.040 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2001 | 106 | 0.040 |
Why?
|
| Lung Neoplasms | 1 | 2006 | 543 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 2020 | 52 | 0.040 |
Why?
|
| Knee Joint | 1 | 2006 | 746 | 0.040 |
Why?
|
| Shoulder Joint | 1 | 2006 | 655 | 0.040 |
Why?
|
| Hip Joint | 1 | 2006 | 544 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2021 | 390 | 0.040 |
Why?
|
| Hemoglobin, Sickle | 1 | 2018 | 1 | 0.040 |
Why?
|
| Iron Overload | 1 | 2018 | 2 | 0.040 |
Why?
|
| Blood Viscosity | 1 | 2018 | 9 | 0.040 |
Why?
|
| Retrospective Studies | 2 | 2023 | 3358 | 0.040 |
Why?
|
| Disease Management | 1 | 2018 | 101 | 0.030 |
Why?
|
| Platelet Glycoprotein GPIb-IX Complex | 1 | 2017 | 4 | 0.030 |
Why?
|
| Protein Multimerization | 1 | 2017 | 17 | 0.030 |
Why?
|
| Pedigree | 1 | 2017 | 55 | 0.030 |
Why?
|
| Homozygote | 1 | 2017 | 19 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2017 | 65 | 0.030 |
Why?
|
| Headache | 1 | 2017 | 38 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2017 | 63 | 0.030 |
Why?
|
| Transfection | 1 | 2017 | 122 | 0.030 |
Why?
|
| Collagen | 1 | 2017 | 85 | 0.030 |
Why?
|
| Protein Binding | 1 | 2017 | 121 | 0.030 |
Why?
|
| Anxiety | 1 | 2018 | 146 | 0.030 |
Why?
|
| Heterozygote | 1 | 2017 | 99 | 0.030 |
Why?
|
| Administration, Intravenous | 1 | 2016 | 23 | 0.030 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2016 | 4 | 0.030 |
Why?
|
| Blood Coagulation Tests | 1 | 2016 | 12 | 0.030 |
Why?
|
| Demography | 1 | 2016 | 71 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2016 | 51 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2017 | 572 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2017 | 367 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2018 | 851 | 0.030 |
Why?
|
| Depression | 1 | 2018 | 412 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2017 | 870 | 0.030 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2018 | 488 | 0.030 |
Why?
|
| Early Ambulation | 1 | 2011 | 17 | 0.020 |
Why?
|
| Intermittent Pneumatic Compression Devices | 1 | 2011 | 7 | 0.020 |
Why?
|
| Ultrasonography, Doppler, Duplex | 1 | 2011 | 15 | 0.020 |
Why?
|
| Vena Cava Filters | 1 | 2011 | 8 | 0.020 |
Why?
|
| Anesthesia, Epidural | 1 | 2011 | 19 | 0.020 |
Why?
|
| Venous Thrombosis | 1 | 2011 | 45 | 0.020 |
Why?
|
| Cell Division | 1 | 2011 | 82 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2011 | 106 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2012 | 207 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2012 | 252 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2011 | 297 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2011 | 326 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2011 | 408 | 0.020 |
Why?
|
| Mice | 1 | 2011 | 1352 | 0.020 |
Why?
|
| Partial Thromboplastin Time | 1 | 2006 | 6 | 0.020 |
Why?
|
| Carboplatin | 1 | 2006 | 25 | 0.020 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2006 | 15 | 0.020 |
Why?
|
| Cyclophosphamide | 1 | 2006 | 46 | 0.020 |
Why?
|
| Paclitaxel | 1 | 2006 | 50 | 0.020 |
Why?
|
| Hyperglycemia | 1 | 2006 | 28 | 0.020 |
Why?
|
| Prednisone | 1 | 2006 | 64 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2011 | 901 | 0.010 |
Why?
|
| Bleeding Time | 1 | 2005 | 1 | 0.010 |
Why?
|
| Drug Evaluation | 1 | 2005 | 19 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2006 | 297 | 0.010 |
Why?
|
| Placenta | 1 | 2004 | 7 | 0.010 |
Why?
|
| Pre-Eclampsia | 1 | 2004 | 7 | 0.010 |
Why?
|
| Administration, Intranasal | 1 | 2005 | 28 | 0.010 |
Why?
|
| Sampling Studies | 1 | 2004 | 30 | 0.010 |
Why?
|
| Immunosuppressive Agents | 1 | 2006 | 115 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2004 | 90 | 0.010 |
Why?
|
| Gestational Age | 1 | 2004 | 73 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2006 | 360 | 0.010 |
Why?
|
| Reference Values | 1 | 2004 | 181 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2006 | 242 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2006 | 160 | 0.010 |
Why?
|
| Cytokines | 1 | 2004 | 225 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2004 | 512 | 0.010 |
Why?
|
| Animals | 1 | 2011 | 3503 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2004 | 473 | 0.010 |
Why?
|